[1] Raghavan S, Vassy JL, Ho YL, et al. Diabetes mellitus-related all-cause and cardiovascular mortality in a national cohort of adults[J]. J Am Heart Assoc,2019,8(4):e11295.
[2] Schmidt AM. Diabetes mellitus and cardiovascular disease[J]. Arterioscler Thromb Vasc Biol,2019,39(4):558-68.
[3] Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes[J]. JAMA,2019,321(17):1720-21.
[4] Han Y, Xie H, Liu Y, et al. Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis[J]. Cardiovasc Diabetol,2019,18(1):96.
[5] Griffin SJ, Leaver JK, Irving GJ. Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes[J]. Diabetologia,2017,60(9):1620-29.
[6] Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med,2016,375(4):311-22.
[7] Scheen AJ. Semaglutide: a promising new glucagon-like peptide-1 receptor agonist[J]. Lancet Diabetes Endocrinol,2017,5(4):236-38.
[8] Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes[J]. N Engl J Med,2016,375(19):1834-44.
[9] Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med,2017,377(13):1228-39.
[10] Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes[J]. N Engl J Med,2017,377(7):644-57.
[11] Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes[J].N Engl J Med, 2019,380(4):347-57.
[12] Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes[J]. N Engl J Med,2015,373(22):2117-28.
[13] Radholm K, Wu JH, Wong MG, et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes - a systematic review[J]. Diabetes Res Clin Pract,2018,140:118-28.
[14] Sinha B, Ghosal S. Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) reduce hospitalization for heart failure only and have no effect on atherosclerotic cardiovascular events: a meta-analysis[J]. Diabetes Ther,2019,10(3):891-99.
[15] Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials[J]. Lancet,2019,393(10166):31-39.
[16] WellsGA, SheaB, O'ConnellD, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of non randomized studies in meta-analysis. Availablefrom:www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
[17] Persson F, Nystrom T, Jorgensen ME, et al. Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: a multinational observational study[J]. Diabetes Obes Metab,2018,20(2):344-51.
[18] Toulis KA, Willis BH, Marshall T, et al. All-cause mortality in patients with diabetes under treatment with dapagliflozin: a population-based, open-cohort study in the health improvement network database[J]. J Clin Endocrinol Metab,2017,102(5):1719-25.
[19] Cahn A, Melzer-Cohen C, Pollack R, et al. Acute renal outcomes with sodium-glucose co-transporter-2 inhibitors: real-world data analysis[J]. Diabetes Obes Metab,2019,21(2):340-48.
[20] Kosiborod M, Lam C, Kohsaka S, et al. Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 Study[J]. J Am Coll Cardiol,2018,71(23):2628-39.
[21] Birkeland KI, Jorgensen ME, Carstensen B, et al. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis[J]. Lancet Diabetes Endocrinol,2017,5(9):709-17.
[22] Udell J A, Yuan Z, Rush T, et al. Cardiovascular outcomes and risks after initiation of a sodium glucose cotransporter 2 inhibitor: results from the EASEL population-based cohort study (evidence for cardiovascular outcomes with sodium glucose cotransporter 2 Inhibitors in the real world)[J]. Circulation,2018,137(14):1450-59.
[23] Dawwas GK, Smith SM, Park H. Cardiovascular outcomes of sodium glucose cotransporter-2 inhibitors in patients with type 2 diabetes[J]. Diabetes Obes Metab,2019,21(1):28-36.
[24] Kosiborod M, Cavender MA, Fu AZ, et al. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors)[J]. Circulation,2017,136(3):249-59.
[25] Cavender MA, Norhammar A, Birkeland KI, et al. SGLT-2 inhibitors and cardiovascular risk: an analysis of CVD-REAL[J]. J Am Coll Cardiol,2018,71(22):2497-06.
[26] Nystrom T, Bodegard J, Nathanson D, et al. Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes[J]. Diabetes Obes Metab,2017,19(6):831-41.
[27] Pasternak B, Ueda P, Eliasson B, et al. Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study[J]. BMJ,2019,366:l4772.
[28] Patorno E, Goldfine AB, Schneeweiss S, et al. Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study[J]. BMJ,2018,360:k119.
[29] Ryan PB, Buse JB, Schuemie MJ, et al. Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: a real-world meta-analysis of 4 observational databases (OBSERVE-4D)[J]. Diabetes Obes Metab,2018,20(11):2585-97.
[30] Norhammar A, Bodegard J, Nystrom T, et al. Dapagliflozin is Associated with lower risk of hospitalization for heart failure, major adverse cardiovascular events and all cause death compared to DPP-4i in T2D patients: CVD-REAL Nordic[J]. Can J Diabetes, 2017, 41(5) : S22-S83.
[31] Usman MS, Siddiqi TJ, Memon MM, et al. Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: a systematic review and meta-analysis[J]. Eur J Prev Cardiol,2018,25(5):495-02.
[32] Zheng SL, Roddick AJ, Aghar-Jaffar R, et al. Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes: a systematic review and meta-analysis[J]. JAMA,2018,319(15):1580-91.